Servier and Scandicure enter into agreement to conduct research in the field of metabolic diseases

03/04/2018
Download as PDF

Paris and Gothenburg, 3 April 2018 – Servier, an independent international pharmaceutical company, and Scandicure, a Swedish spin-out of the University of Gothenburg, today announced the establishment of an agreement to exploit Scandicure’s innovation in the field of metabolic disease.

 

Scandicure, in collaboration with the IMI[1]-funded European Lead Factory, has developed inhibitors of a novel biological target for non-alcoholic steatohepatitis (NASH), type-2 diabetes and potentially other metabolic diseases.

Servier will continue research started by Scandicure and advance Scandicure’s novel compounds through preclinical development using Servier’s drug discovery capabilities and knowledge of the disease areas. Under the terms of the agreement, Servier shall provide Scandicure with an upfront payment, as well as pre-clinical and clinical milestones.

“We have identified a new attractive target in metabolic diseases, and the European Lead Factory has provided an access to a high-quality compound library and a platform of expertise for high-throughput screening. This unique combination of a well-validated target with the high-quality output of the European Lead Factory has provided Scandicure with strong starting points for new and transformative treatments in NASH and related diseases,” stated Dr. Margit Mahlapuu, founder and CEO of Scandicure. “Servier with its deep and integrated capabilities throughout the entire pharmaceutical R&D chain, is an ideal partner for Scandicure in this development initiative”.

“Our access to Scandicure’s target-knowledge and novel chemistry allows us to explore an important pathway in metabolic diseases. Our goal is to find treatments for patients who suffer from NASH, who are underserved by current therapies”, said Claude Bertrand, General Director of Research and Development at Servier. “This agreement illustrates Servier’s continued commitment to novel approaches to diseases where significant unmet medical needs still exist”.

 

[1] IMI : Innovative Medecines Initiative